pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Results of univariable and multivariable Cox regression analyses for overall survival in all patients

Variable Univariable Cox Multivariable Cox

HR (95% CI) p-value HR (95% CI) p-value
Medication (pembrolizumab vs nivolumab) 0.45 (0.21-0.99) 0.046 0.49 (0.22-1.07) 0.075
Type of cancers (others vs NSCLC) 2.01 (1.07-3.78) 0.031 1.87 (0.99-3.54) 0.055
PD-L1 expression (≥50% vs <50%) 0.39 (0.16-0.93) 0.034
Korean J Clin Pharm 2020;30:11-8 https://doi.org/10.24304/kjcp.2020.30.1.11
© 2020 Korean J Clin Pharm